Skip to main content

CCTG at the International Conference on Malignant Lymphoma

CCTG at the International Conference on Malignant Lymphoma
The following presentations are being given at the International Conference on Malignant Lymphoma in Lugano Switzerland, 17-21 June 2025. The abstracts are now published in Hematological Oncology.
 
LY12 - poster
The definition of primary refractory large B cell lymphoma (LBCL) has varied across studies. There is limited trial data on the time to relapse (TTR) from end of primary chemoimmunotherapy and its impact on outcomes. In this secondary analysis of the CCTG trial LY.12 (NCT00078949), we assess the relationship between TTR and outcomes to better define the high-risk patient (pt) group.
 
Gong IY, Kuruvilla J, Prica A, Olney H, Fraser G, Buckstein R, Skrabek P, Keating M, Hay A, Shepherd L, Chen B, Crump M. Defining primary refractory disease in large B cell lymphoma and its association with outcomes: A secondary analysis of the LY.12 clinical trial. International Conference on Malignant Lymphoma. Hematological Oncology 43 [S3], e308_70094. 2025.
 
HD6 pooled analysis - oral presentation
Early-stage classic Hodgkin lymphoma (cHL) has historically been classified as favorable or unfavorable. However, the importance of these factors has not been rigorously examined in the modern era, and the variables used are dichotomized, subjective or difficult to measure. Leveraging patient (pt)-level data from global clinical trials and registries within the HoLISTIC consortium, researchers developed and validated the early-stage cHL International Prognostication Index (E-HIPI) to predict 2-year (yr) progression-free survival (PFS) utilizing objective, continuous, and readily measurable variables.
 
Evens AM, Rodday A, Maurer MJ, Upshaw JN, Counsell N, Rossetti S, Chang C, Cui Z, Xiang Q, Mwangi R, Advani R, Andre M, Gallamini A, Hay AE, Hodgson DC, Hoppe RT, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J, Savage KJ, Parsons SK, Radford J. The early-stage classic Hodgkin Lymphoma international prognostication index (E-HIPI): An individualized prediction model utilizing objective and continuous variables. International Conference on Malignant Lymphoma. Hematology Oncology 43 [S3], e126_70093. 2025.
 
LY18 - e-poster (supplement abstract)